Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Ribociclib. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK4 known ✓ | P11802 | 14/20 | 1.00 |
| ▸ | CDK6 known ✓ | Q00534 | 4/20 | 1.00 |
| ▸ | CCND1 | P24385 | 8/20 | 1.00 |
| ▸ | CDK2 | P24941 | 3/20 | 1.00 |
| ▸ | CCND3 | P30281 | 2/20 | 1.00 |
| ▸ | GAK | O14976 | 1/20 | 1.00 |
| ▸ | CCNT1 | O60563 | 1/20 | 1.00 |
| ▸ | CCNA2 | P20248 | 1/20 | 1.00 |
| ▸ | FECH | P22830 | 1/20 | 1.00 |
| ▸ | CDK9 | P50750 | 1/20 | 1.00 |
| ▸ | CDK16 | Q00536 | 1/20 | 1.00 |
| ▸ | MAP3K1 | Q13233 | 1/20 | 1.00 |
| ▸ | CAMK2G | Q13555 | 1/20 | 1.00 |
| ▸ | CAMK2D | Q13557 | 1/20 | 1.00 |
| ▸ | Q6ZSR9 | Q6ZSR9 | 1/20 | 1.00 |
| ▸ | PRKD2 | Q9BZL6 | 1/20 | 1.00 |
| ▸ | SIK2 | Q9H0K1 | 1/20 | 1.00 |
| ▸ | CDK1 | P06493 | 3/20 | 0.95 |
| ▸ | CCND2 | P30279 | 1/20 | 0.72 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ribociclib SCHEMBL29912679 | 1.00 | CDK4 (1.00) | CDK4CCND1CDK6CDK2CCND3 | |
| Ribociclib SCHEMBL29385337 | 1.00 | CDK4 (1.00) | CDK4CCND1CDK6CDK2CCND3 | |
| Ribociclib SCHEMBL29384231 | 1.00 | CDK4 (1.00) | CDK4CCND1CDK6CDK2CCND3 | |
| Ribociclib SCHEMBL29390270 | 0.99 | CDK4 (0.98) | CDK4CCND1CDK6CDK2CCND3 | |
| Ribociclib SCHEMBL1998188 | 0.99 | CDK4 (0.98) | CDK4CCND1CDK6CDK2CCND3 | |
| SCHEMBL31607940 | 0.98 | CDK4 (0.97) | CDK4CCND1CDK6CDK2CCND3 | |
| SCHEMBL1993460 | 0.98 | CDK2 (1.00) | CDK4CCND1CDK6CDK2CCND3 | |
| Ribociclib SCHEMBL29414075 | 0.95 | CDK4 (0.91) | CDK4CCND1CDK6CDK2CCND3 | |
| Ribociclib SCHEMBL2684999 | 0.95 | CDK4 (0.91) | CDK4CCND1CDK6CDK2CCND3 | |
| SCHEMBL31607869 | 0.95 | CDK4 (0.91) | CDK4CCND1CDK6CDK2CCND3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 9078 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260144778-A1 | REGIMENS OF ESTROGEN RECEPTOR ANTAGONISTS | OLEMA PHARMACEUTICALS, INC. (US) | 2026-05-28 | — | — | US | claimed |
| US-20260144794-A1 | THERAPEUTIC COMPOSITIONS AND METHODS FOR TREATING CANCERS | Pattern Computer, Inc. (US) | 2026-05-28 | — | — | US | claimed |
| CN-122075716-A | Medicine for treating tumor by combining recombinant oncolytic virus and small-molecule anticancer medicine | — | 2026-05-26 | — | — | CN | claimed |
| CN-122070932-A | Application of combination of decitabine and anti-HER 2 antibody in preparation of medicines for treating tumors | 上海交通大学 | 2026-05-22 | — | — | CN | claimed |
| WO-2026103886-A1 | PHARMACEUTICAL COMPOSITION, KIT AND USE THEREOF | 浙江扬厉医药技术有限公司 | 2026-05-21 | — | — | WO | claimed |
| WO-2026105121-A1 | ANTICANCER FORMULATIONS AND USES THEREOF | INTRAGEL THERAPEUTICS LTD. (IL) | 2026-05-21 | — | — | WO | claimed |
| EP-4743069-A1 | STABLE SOLID DISPERSIONS OF SALCAPROZATE WITH VARIOUS ACTIVE PHARMACEUTICAL INGREDIENTS | Biophore India Pharmaceuticals Pvt. Ltd. (IN) | 2026-05-20 | — | — | EP | claimed |
| US-12629363-B2 | Prophylaxis and treatment of angioedema | PHARVARIS GMBH (CH) | 2026-05-19 | — | — | US | claimed |
| CN-122070145-A | Methods and medicaments for the treatment of endometriosis | 英矽智能科技知识产权有限公司 | 2026-05-19 | — | — | CN | claimed |
| WO-2026102161-A1 | METHODS OF TREATING OVARIAN AND PANCREATIC CANCER | CONCARLO THERAPEUTICS, INC. (US) | 2026-05-15 | — | — | WO | claimed |
| EP-2558092-A1 | COMBINATION COMPRISING A CYCLIN DEPENDENT KINASE 4 OR CYCLIN DEPENDENT KINASE (CDK4/6) INHIBITOR AND AN MTOR INHIBITOR FOR TREATING CANCER | Novartis AG (CH) | 2013-02-20 | — | — | EP | claimed |
| US-20130035336-A1 | COMBINATION COMPRISING A CYCLIN DEPENDENT KINASE 4 OR CYCLIN DEPENDENT KINASE (CDK4/6) INHIBITOR FOR TREATING CANCER | NOVARTIS AG (CH) | 2013-02-07 | — | — | US | claimed |
| WO-2012064805-A1 | SALT(S) OF 7-CYCLOPENTYL-2 -(5-PIPERAZIN-1-YL-PYRIDIN-2-YLAMINO)-7H-PYRROLO[2,3-D]PYRIMIDINE-6-CARBOXYLIC ACID DIMETHYLAMIDE AND PROCESSES OF MAKING THEREOF | NOVARTIS AG (CH) | 2012-05-18 | — | — | WO | claimed |
| US-20120115878-A1 | SALT(S) OF 7-CYCLOPENTYL-2-(5-PIPERAZIN-1-YL-PYRIDIN-2-YLAMINO)-7H-PYRROLO[2,3-D]PYRIMIDINE-6-CARBOXYLIC ACID DIMETHYLAMIDE AND PROCESSES OF MAKING THEREOF | CALIENNI JOHN VINCENT (US) | 2012-05-10 | — | — | US | claimed |
| JP-2012500785-A | — | — | 2012-01-12 | — | — | JP | claimed |
| WO-2011130232-A1 | COMBINATION COMPRISING A CYCLIN DEPENDENT KINASE 4 OR CYCLIN DEPENDENT KINASE (CDK4/6) INHIBITOR AND AN MTOR INHIBITOR FOR TREATING CANCER | NOVARTIS AG (CH) | 2011-10-20 | — | — | WO | claimed |
| US-20110152244-A1 | PYRROLOPYRIMIDINE COMPOUNDS AND THEIR USES | NOVARTIS AG (CH) | 2011-06-23 | — | — | US | claimed |
| EP-2331547-A1 | PYRROLOPYRIMIDINE COMPOUNDS AS CDK INHIBITORS | Novartis AG (CH) | 2011-06-15 | — | — | EP | claimed |
| US-20100105653-A1 | PYRROLOPYRIMIDINE COMPOUNDS AND THEIR USES | NOVARTIS AG | 2010-04-29 | — | — | US | claimed |
| WO-2010020675-A1 | PYRROLOPYRIMIDINE COMPOUNDS AS CDK INHIBITORS | NOVARTIS AG (CH) | 2010-02-25 | — | — | WO | claimed |